# Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema

**Authors:** Aaron Yarlas, Alexandra J. Feld, Jakob B. Bjorner, Cary Thurm, Laura Bordone, Kenneth B. Newman, Sabrina Treadwell, Danny M. Cohn

PMC · DOI: 10.1002/clt2.70143 · Clinical and Translational Allergy · 2026-01-12

## TL;DR

This study shows that the Angioedema Control Test (AECT) is a reliable way to measure how well hereditary angioedema is controlled, based on actual attack rates.

## Contribution

The study demonstrates the criterion validity of the AECT for the first time using objective attack rate data.

## Key findings

- AECT scores correlated strongly with HAE attack rates (ρ = −0.40 to −0.85).
- Patients with higher AECT scores had significantly lower attack rates.
- 97.4% of patients with the highest AECT score had zero attacks.

## Abstract

Hereditary angioedema (HAE), defined by unpredictable, painful, acute swelling attacks affecting several bodily locations, diminishes patients' quality of life. Assessing disease activity, burden, and treatment response pose challenges in routine care. The patient‐reported Angioedema Control Test (AECT) is a subjective measure of HAE disease control. Criterion validity of AECT with objective measures of disease control has not been previously assessed. This study evaluates the criterion validity of AECT using investigator‐confirmed HAE attack rate in patients with HAE.

The Phase 3 OASIS‐HAE study (NCT05139810) randomized patients with HAE to receive donidalorsen 80 mg or placebo subcutaneously for 24 weeks. The full analysis population included all dosed patients (N = 90), pooled across treatment arms. This post‐hoc analysis examined the correlation between AECT and HAE attacks at Baseline, 12, and 24 weeks.

AECT scores correlated moderately to strongly with HAE attack rate (ρ = −0.40 to −0.85). Mean attack rates differed significantly between poor (AECT < 10) and well‐controlled (AECT ≥ 10) disease subgroups at study visits. At Week 24, 97.4% of patients reporting complete disease control (AECT maximum score of 16) had an attack rate of 0; the remaining patient had 1 attack. Patients with no attacks had a mean AECT score of 15.1 versus 7.7 for patients with attack rates > 0.

This study supports the criterion validity of AECT in patients with HAE scores. AECT scores were strongly associated with objective disease control. AECT may be a valuable tool for monitoring disease control in patients with HAE.

## Linked entities

- **Diseases:** Hereditary angioedema (MONDO:0019623), HAE (MONDO:0019623)

## Full-text entities

- **Genes:** KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}
- **Diseases:** swelling (MESH:D004487), larynx (MESH:D007818), tract (MESH:D014570), depression (MESH:D003866), urticaria (MESH:D014581), anxiety (MESH:D001007), Angioedema (MESH:D000799), swelling of the skin (MESH:D012871), pain (MESH:D010146), HAE (MESH:D054179), AECT (MESH:D013736), gastroenteritis (MESH:D005759), fatigue (MESH:D005221), type I or II HAE (MESH:D056829)
- **Chemicals:** donidalorsen (MESH:C000723381)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12795239/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12795239/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12795239/full.md

---
Source: https://tomesphere.com/paper/PMC12795239